2020 / 04

Следующая статья
DOI: 10.24075/vrgmu.2020.048

ОРИГИНАЛЬНОЕ ИССЛЕДОВАНИЕ

Масс-спектрометрическое исследование и теоретическое моделирование комплексов флуконазола с аланином, лизином и треонином

В. В. Чаговец, Н. Л. Стародубцева, В. Е. Франкевич
Информация об авторах

Национальный медицинский исследовательский центр акушерства, гинекологии и перинатологии имени В. И. Кулакова, Москва, Россия

Для корреспонденции: Виталий Викторович Чаговец
ул. Академика Опарина, д. 4, г. Москва, 117198; moc.liamg@stevogahcvv

Информация о статье

Финансирование: работа выполнена в рамках соглашения № 05.604.21.0241 «Разработка технологии персонализированного лечения матерей и новорожденных с инфекционно-воспалительными заболеваниями, вызванными мультирезистентными штаммами микроорганизмов, на основании генотипирования возбудителей и терапевтического лекарственного мониторинга антимикробных препаратов» (мероприятие 1,2, очередь 1) Министерства науки и высшего образования РФ. Программа: «Исследование и разработка по приоритетным направлениям развития научно- технологического комплекса России на 2014–2020 годы». Уникальный идентификатор проекта RFMEFI60419X0241.

Вклад авторов: В. В. Чаговец, В. Е. Франкевич, Н. Л. Стародубцева — концепция и дизайн исследования, обработка материала; В. В. Чаговец — статистическая обработка данных; В. В. Чаговец, Н. Л. Стародубцева — написание текста; В. Е. Франкевич — редактирование.

Статья получена: 22.07.2020 Статья принята к печати: 13.08.2020 Опубликовано online: 23.08.2020
|
  1. Balding PR, Porro CS, McLean KJ, Sutcliffe MJ, Maréchal JD, Munro AW, et al. How do azoles inhibit cytochrome P450 enzymes? A density functional study. J Phys Chem A. 2008; 112 (50): 12911–8.
  2. Lupetti A, Danesi R, Campa M, Tacca M Del, Kelly S. Molecular basis of resistance to azole antifungals. Trends Mol Med. 2002; 8 (2): 76–81.
  3. Marichal P, Gorrens J, Laurijssens L, Vermuyten K, Van Hove C, Le Jeune L, et al. Accumulation of 3-ketosteroids induced by itraconazole in azole- resistant clinical Candida albicans isolates. Antimicrob Agents Chemother. 1999; 43 (11): 2663–70.
  4. White TC, Marr KA, Bowden RA. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin Microbiol Rev. 1998; 11 (2): 382–402.
  5. Shapiro RS, Robbins N, Cowen LE. Regulatory Circuitry Governing Fungal Development, Drug Resistance, and Disease. Microbiol Mol Biol Rev. 2011; 75 (2): 213–267.
  6. Doğan İS, Saraç S, Sari S, Kart D, Eşsiz Gökhan Ş, Vural İ, et al. New azole derivatives showing antimicrobial effects and their mechanism of antifungal activity by molecular modeling studies. Eur J Med Chem. 2017; 130: 124–38.
  7. Jacob K S, Ganguly S, Kumar P, Poddar R, Kumar A. Homology model, molecular dynamics simulation and novel pyrazole analogs design of Candida albicans CYP450 lanosterol 14 α-demethylase, a target enzyme for antifungal therapy. J Biomol Struct Dyn. 2017; 35 (7): 1446–63.
  8. Gao P, Cui YL, Wu RL. Molecular dynamic modeling of CYP51B in complex with azole inhibitors. J Biomol Struct Dyn. 2018; 36 (6): 1511–9.
  9. Keighobadi M, Emami S, Lagzian M, Fakhar M, Rafiei A, Valadan R. Molecular modeling and structural stability of wild-type and mutant CYP51 from leishmania major: In vitro and in silico analysis of a laboratory strain. Molecules. 2018; 23 (3). DOI: 10.3390/ molecules23030696.
  10. Vijayakumar S, Das P. Structural, molecular motions, and free- energy landscape of Leishmania sterol-14α-demethylase wild type and drug resistant mutant: a comparative molecular dynamics study. J Biomol Struct Dyn. 2019; 37 (6): 1477–93.
  11. Honorato Siqueira T, Martínez L. Molecular simulations of fluconazole-mediated inhibition of sterol biosynthesis. J Biomol Struct Dyn. 2020; 38 (6): 1659–69.
  12. Kontoyianni M, Lacy B. Toward Computational Understanding of Molecular Recognition in the Human Metabolizing Cytochrome P450s. Curr Med Chem. 2018; 25 (28): 3353–73.
  13. Lepesheva GI, Waterman MR. Sterol 14α-demethylase cytochrome P450 (CYP51), a P450 in all biological kingdoms. Biochim Biophys Acta — Gen Subj. 2007; 1770 (3): 467–77.
  14. Lepesheva GI, Waterman MR. Structural basis for conservation in the CYP51 family. Biochim Biophys Acta — Proteins Proteomics. 2011; 1814 (1): 88–93.
  15. Loo JA. Studying noncovalent protein complexes by electrospray ionization mass spectrometry. Mass Spectrom Rev. 1997; 16 (1): 1–23.
  16. Pramanik BN, Bartner PL, Mirza UA, Liu YH, Ganguly AK. Electrospray ionization mass spectrometry for the study of non- covalent complexes: An emerging technology. J Mass Spectrom. 1998; 33 (10): 911–20.
  17. Loo JA. Electrospray ionization mass spectrometry: A technology for studying noncovalent macromolecular complexes. Int J Mass Spectrom. 2000; 200 (1–3): 175–86.
  18. Ray SS, Singh SK, Balaram P. Sulfonate (ANS) Binding to Proteins. Data Process. 2001; 0305 (01).
  19. Zhang S, Van Pelt CK, Wilson DB. Quantitative determination of noncovalent binding interactions using automated nanoelectrospray mass spectrometry. Anal Chem. 2003; 75 (13): 3010–8.
  20. Tjernberg A, Carnö S, Oliv F, Benkestock K, Edlund PO, Griffiths WJ, et al. Determination of dissociation constants for protein-ligand complexes by electrospray ionization mass spectrometry. Anal Chem. 2004; 76 (15): 4325–31.
  21. Benkestock K. Electrospray Ionization Mass Spectrometry for Determination of Noncovalent Interactions in Drug Discovery. 2008.
  22. Bligh SWA, Haley T, Lowe PN. Measurement of dissociation constants of inhibitors binding to Src SH2 domain protein by non-covalent electrospray ionization mass spectrometry. J Mol Recognit. 2003; 16 (3): 139–48.
  23. Zhang C, Chen H, Guymon AJ, Wu G, Cooks RG, Ouyang Z. Instrumentation and methods for ion and reaction monitoring using a non-scanning rectilinear ion trap. Int J Mass Spectrom. 2006; 255–256 (1–3): 1–10.
  24. Wu RF, Huang YD, Chu YQ, Liu ZP, Ding CF. Investigation of Non-covalent Interactions of 18-Crown-6 with Amino Acids in Gas Phase by Mass Spectrometry. Chinese J Anal Chem. 2018; 46 (2): 273–9.
  25. Zhang S, Van Pelt CK, Wilson DB. Quantitative determination of noncovalent binding interactions using automated nanoelectrospray mass spectrometry. Anal Chem. 2003; 75 (13): 3010–8.
  26. Mayne CG, Saam J, Schulten K, Tajkhorshid E, Gumbart JC. Rapid parameterization of small molecules using the force field toolkit. J Comput Chem. 2013; 34 (32): 2757–70.
  27. Vanommeslaeghe K, Raman EP, MacKerell AD. Automation of the CHARMM General Force Field (CGenFF) II: Assignment of Bonded Parameters and Partial Atomic Charges. J Chem Inf Model. 2012; 52 (12): 3155–68.
  28. Vanommeslaeghe K, Hatcher E, Acharya C, Kundu S, Zhong S, Shim J, et al. CHARMM general force field: A force field for drug-like molecules compatible with the CHARMM all-atom additive biological force fields. J Comput Chem. 2010; 31 (4): 671–90.
  29. Schmidt MW, Baldridge KK, Boatz JA, Elbert ST, Gordon MS, Jensen JH, et al. General atomic and molecular electronic structure system. J Comput Chem. 1993; 14 (11): 1347–63.